P527 Factors associated with choice of treatment regimen after the induction period in patients with Ulcerative Colitis treated with vedolizumab

S Vuksanovic,J Spiric,A Toplicanin,A Nikolic,I Jovicic,S Djuranovic,D Popovic,S Dragasevic,A Sokic Milutinovic

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0657

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background Vedolizumab (VDZ) is a selective, alpha4-beta7 anti-integrin antibody used for treatment of inflammatory bowel diseases. The aim of our study was to investigate factors that influence the decision making and determine further therapeutic regimen after the induction period in patients with ulcerative colitis treated with VDZ and to identify predictors for early response to VDZ. Methods A retrospective study conducted at the Clinic for gastroenterohepatology, University Clinical Center Serbia included 89 patients with ulcerative colitis (mean age 47±15; 45 males) treated with VDZ (69 bio-naïve and 20 previously exposed to anti-TNF). Localization of disease, endoscopic score at the beginning of therapy, together with CRP and fecal calprotectin levels before the initiation of therapy and at week 14, and prior exposure to anti-TNF in relation to the treatment regimen at the end of the induction period were analyzed. Results After induction therapy total of 55 patients (61.8%) continued with standard dosing regimen, while in 34 patients (38.2%) shortening the interval to 4 weeks as optimization of VDZ treatment was prescribed. Patients whose treatment regimen was optimized at week 14 had had statistically significantly higher baseline CRP levels (p=0.025), as well as CRP levels at week 14 (p=0.002) and fecal calprotectin at week 14 (p=0.000), while there was no difference in the baseline fecal calprotectin between patients in standard and optimized regimen (p=1.000). There was no statistical difference in localization of disease and prior anti-TNF exposure between these two groups of patients (p=0.732 and p=0.449, respectively). Conclusion Higher CRP and fecal calprotectin levels at week 14 were determining factors for optimization of VDZ treatment. Higher levels of CRP before biologic therapy was started was associated with the increased need for optimized regiment at week 14. Extensive disease and prior anti-TNF exposure did not correlate with need for optimization of treatment after the induction period.

gastroenterology & hepatology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is, during the treatment of patients with ulcerative colitis (UC) using vedolizumab (VDZ), which factors will influence the choice between continuing the standard - dose regimen or optimizing the treatment regimen (i.e., shortening the dosing interval to 4 weeks) after the induction period. Specifically, the researchers aimed to explore the factors influencing the decision - making and identify the indicators predicting the early response to VDZ.

The research background indicates that vedolizumab is a selective α4β7 anti - integrin antibody used for treating inflammatory bowel diseases. By retrospectively analyzing the clinical data of 89 UC patients, the researchers analyzed factors such as disease location, endoscopic scores before treatment and at week 14, C - reactive protein (CRP) levels, fecal calprotectin levels, and previous exposure to anti - TNF treatment, in order to evaluate how these factors affect the treatment choice after the induction period.

The research results show that after induction treatment, 55 patients (61.8%) continued with the standard - dose regimen, while 34 patients (38.2%) were adjusted to the optimized treatment regimen once every 4 weeks. Those patients who required the optimized treatment regimen at week 14 had significantly higher CRP levels at baseline and at week 14 (\(p = 0.025\) and \(p=0.002\)), and significantly higher fecal calprotectin levels at week 14 (\(p = 0.000\)). In addition, the study found that higher CRP levels before the start of biological treatment were associated with an increased need for optimized treatment at week 14. However, the extent of the disease and previous anti - TNF exposure had no significant correlation with the need for optimizing the treatment regimen after the induction period.

In conclusion, this study reveals that when treating UC patients with VDZ, CRP and fecal calprotectin levels are the key factors in determining whether it is necessary to optimize the treatment regimen after the induction period.